MoonLake Immunotherapeutics
$ 15.79
1.09%
11 Feb - close price
- Market Cap 1,106,636,000 USD
- Current Price $ 15.79
- High / Low $ 15.87 / 15.44
- Stock P/E N/A
- Book Value 4.54
- EPS -3.33
- Next Earning Report 2026-02-25
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.31 %
- ROE -0.54 %
- 52 Week High 62.75
- 52 Week Low 5.95
About
None
Analyst Target Price
$19.03
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-05 | 2025-05-05 | 2025-02-26 | 2024-11-12 | 2024-08-07 | 2024-05-07 | 2024-02-29 | 2023-11-14 | 2023-08-10 | 2023-05-12 | 2023-03-20 |
| Reported EPS | -1.1 | -0.87 | -0.63 | -0.72 | -0.56 | -0.39 | -0.22 | -0.12 | -0.18 | -0.23 | -0.23 | -0.31 |
| Estimated EPS | -0.8788 | -0.72 | -0.7355 | -0.5928 | -0.44 | -0.28 | -0.19 | -0.23 | -0.23 | -0.27 | -0.31 | -0.33 |
| Surprise | -0.2212 | -0.15 | 0.1055 | -0.1272 | -0.12 | -0.11 | -0.03 | 0.11 | 0.05 | 0.04 | 0.08 | 0.02 |
| Surprise Percentage | -25.1707% | -20.8333% | 14.344% | -21.4575% | -27.2727% | -39.2857% | -15.7895% | 47.8261% | 21.7391% | 14.8148% | 25.8065% | 6.0606% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-25 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.97 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MLTX
2026-01-18 08:28:18
MoonLake Immunotherapeutics (MLTX) is under scrutiny after the FDA allowed it to proceed with a Biologics License Application for Sonelokimab, leading to recent share price volatility. Despite a 4.1x Price-to-Book ratio, which is considered overvalued compared to peers and the US biotech industry average, the company has no reported revenue and significant annual losses. This valuation reflects market confidence in its pipeline rather than current financial performance, amid ongoing clinical and regulatory uncertainties.
2026-01-16 09:28:26
Levi & Korsinsky, LLP has filed a class action securities lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) on behalf of shareholders who suffered losses between March 10, 2024, and September 29, 2025. The lawsuit alleges that MoonLake made false statements regarding its drug candidate, SLK, particularly its purported superiority to existing monoclonal antibodies like BIMZELX. Affected investors are encouraged to contact Levi & Korsinsky before December 15, 2025, to learn about their rights to potentially recover losses.
2025-12-20 08:09:06
The Gross Law Firm is urging shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) who incurred losses during the class period of March 10, 2024, to September 29, 2025, to join a class action lawsuit. The complaint alleges that the company made false or misleading statements regarding its sole drug candidate, SLK, particularly its purported superiority over BIMZELX. Shareholders have until December 15, 2025, to register as lead plaintiff.
2025-12-18 09:09:06
Bleichmar Fonti & Auld LLP has filed a securities class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) and its executives. The lawsuit alleges that MoonLake misled investors regarding the efficacy of its drug sonelokimab, leading to a significant stock price drop after disappointing Phase 3 trial results. Investors who purchased MoonLake common stock have until December 15, 2025, to seek appointment as lead plaintiff in the case.
2025-12-17 07:09:28
A class action lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ:MLTX) based on alleged securities fraud between March 10, 2024, and September 29, 2025. Shareholders who suffered losses due to purportedly false statements concerning the company's sole drug candidate, SLK, and its clinical benefits compared to BIMZELX, are encouraged to join the class action before December 15, 2025. Levi & Korsinsky, LLP is representing the aggrieved shareholders.
2025-12-17 04:09:14
A class action lawsuit has been filed against MoonLake Immunotherapeutics (MLTX) alleging securities fraud due to false statements made between March 10, 2024, and September 29, 2025. The lawsuit claims that the company misrepresented the superiority of its drug candidate, SLK, compared to BIMZELX, despite sharing molecular targets. Shareholders who suffered losses during this period are encouraged to contact Levi & Korsinsky by December 15, 2025, to learn about their rights.
